ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 994

Validation Studies of the American College of Rheumatology (ACR) 2010 Fibromyalgia Diagnostic Criteria and the 2011 Self-Report Modification for Survey and Clinical Research

Frederick Wolfe1, Daniel J. Clauw2, MaryAnn FitzCharles3, Don Goldenerberg4, Winfried Häuser5, Robert S. Katz6, Philip J. Mease7, Anthony Russell8, I Jon Russell9 and Brian Walitt10, 1National Data Bank, Wichita, KS, 2Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, 3Rheumatology, McGill University, Montreal, QC, Canada, 4Newton-Wellesley Hospital and Tufts University School of Medicine, Newton, MA., Newton, MA, 5Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany, 6Rush University Medical Center, Chicago, IL, 7Swedish Medical Center and University of Washington, Seattle, WA, 8Medicine, University of Alberta, Edmonton, AB, Canada, 9Arthritis & Osteoporosis Ctr of South Texas, San Antonio, TX, 10National Institutes of Health, National Institute of Nursing Research, Bethesda, DC

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The provisional criteria of the American College of Rheumatology (ACR) 2010 and the 2011 self-report modification for survey and clinical research are widely used for fibromyalgia diagnosis. To determine the validity, usefulness, potential problems and modifications required for the criteria, we assessed multiple research reports published in 2010-2015 in order to provide a 2016 update to the criteria.

Methods: We reviewed 14 validation studies that compared 2010/2011 criteria with ACR 1990 gold standard classification and clinical criteria, as well as epidemiology, clinical and databank studies that addressed important criteria-level variables, including the polysymptomatic distress (PSD) scale – also known as the fibromyalgia severity (FS) scale. Based on definitional differences between 1990 and 2010/2011 criteria, we interpreted 85% sensitivity and 90% specificity as excellent agreement.

Results: Against 1990 and clinical criteria, the median sensitivity and specificity of the 2010/2011 criteria was 86% and 90% (Figure 1). There was a strong association between ACR 1990 tender point levels in cases and controls, and among 2010/2011 PSD/FS scale results (Figure 2). Data from the ACR 2010 study indicated the correlation between tender points and PSD/FS scale was 0.781. Plotting the levels of PSD in FM (+) and FM (-) cases (Figure 3) provided further insight into the effect of symptom severity on diagnosis. Fibromyalgia is milder in population studies. Studies of fibromyalgia criteria are sensitive to selection issues and severity, and to characteristics of control subjects. Various study authors were uncertain as to how to interpret criteria in the presence of other medical disorders. 2010/2011 criteria led to misclassification when applied to regional pain syndromes, but when a test modified widespread pain criterion was added misclassification was eliminated.

Conclusion: The fibromyalgia criteria have good sensitivity and specificity, and were perceived as useful and easy to use. Results of these analyses will be incorporated into revised criteria to eliminate observed problems. :fig1ab.png

:fig2ab.png

:fig3ab.png


Disclosure: F. Wolfe, None; D. J. Clauw, Pfizer, Lilly, Tonix, Zynerba, Apptinix, Cerephex, IMC, 5,Paizer, Lilly, Cerephex, Tonix, 2; M. FitzCharles, None; D. Goldenerberg, None; W. Häuser, None; R. S. Katz, None; P. J. Mease, Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Pharma, 2,Abbive, Amgen, BMS, Celgene, Crescendo, Corrona, Dermira, Janssen, Lilly, Merck, Novartis, Pfizer, Sun, UCB Pharma, Zynerba, 5,Abbvie, Amgen, BMS, Celgene, Crescendo, Genentech, Janssen, Novartis, Pfizer, UCB Pharma, 8; A. Russell, None; I. J. Russell, None; B. Walitt, None.

To cite this abstract in AMA style:

Wolfe F, Clauw DJ, FitzCharles M, Goldenerberg D, Häuser W, Katz RS, Mease PJ, Russell A, Russell IJ, Walitt B. Validation Studies of the American College of Rheumatology (ACR) 2010 Fibromyalgia Diagnostic Criteria and the 2011 Self-Report Modification for Survey and Clinical Research [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validation-studies-of-the-american-college-of-rheumatology-acr-2010-fibromyalgia-diagnostic-criteria-and-the-2011-self-report-modification-for-survey-and-clinical-research/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-studies-of-the-american-college-of-rheumatology-acr-2010-fibromyalgia-diagnostic-criteria-and-the-2011-self-report-modification-for-survey-and-clinical-research/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology